NO20013586L - Bis-sulfonamider - Google Patents

Bis-sulfonamider

Info

Publication number: NO20013586L
Authority: NO; Norway
Prior art keywords: lower alkyl; heteroaryl; aryl; heterocyclyl; alkyl
Prior art date: 1999-09-03

Application number

NO20013586A

Other languages

English (en)

Norwegian (no)

Other versions

NO20013586D0 (no

Inventor

Martin Bolli

Christoph Boss

Martine Clozel

Walter Fischli

Original Assignee

Actelion Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-03

Filing date

2001-07-20

Publication date

2001-07-20

2001-07-20 Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd

2001-07-20 Publication of NO20013586D0 publication Critical patent/NO20013586D0/no

2001-07-20 Publication of NO20013586L publication Critical patent/NO20013586L/no

Links

229940124530 sulfonamide Drugs 0.000 title abstract 3
125000000217 alkyl group Chemical group 0.000 abstract 31
125000003282 alkyl amino group Chemical group 0.000 abstract 6
125000003342 alkenyl group Chemical group 0.000 abstract 5
125000003545 alkoxy group Chemical group 0.000 abstract 5
125000004414 alkyl thio group Chemical group 0.000 abstract 5
125000001072 heteroaryl group Chemical group 0.000 abstract 5
125000003118 aryl group Chemical group 0.000 abstract 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 4
102000017914 EDNRA Human genes 0.000 abstract 3
101150062404 EDNRA gene Proteins 0.000 abstract 3
102000017930 EDNRB Human genes 0.000 abstract 3
101150001833 EDNRB gene Proteins 0.000 abstract 3
125000000304 alkynyl group Chemical group 0.000 abstract 3
125000000623 heterocyclic group Chemical group 0.000 abstract 3
-1 Sulfonamide compounds Chemical class 0.000 abstract 2
125000000753 cycloalkyl group Chemical group 0.000 abstract 2
125000001475 halogen functional group Chemical group 0.000 abstract 2
BCRJIIJVFJJYRD-UHFFFAOYSA-N n-[3-[6-[(4-tert-butylphenyl)sulfonylamino]-2-cyclopropyl-5-(2-methoxyphenoxy)pyrimidin-4-yl]oxypropyl]thiophene-2-sulfonamide Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C2CC2)OCCCNS(=O)(=O)C=2SC=CC=2)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 BCRJIIJVFJJYRD-UHFFFAOYSA-N 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
102000002045 Endothelin Human genes 0.000 abstract 1
108050009340 Endothelin Proteins 0.000 abstract 1
208000001953 Hypotension Diseases 0.000 abstract 1
125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
230000003257 anti-anginal effect Effects 0.000 abstract 1
230000001088 anti-asthma Effects 0.000 abstract 1
230000000844 anti-bacterial effect Effects 0.000 abstract 1
230000003178 anti-diabetic effect Effects 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
230000002460 anti-migrenic effect Effects 0.000 abstract 1
230000002869 anti-sickling effect Effects 0.000 abstract 1
230000000767 anti-ulcer Effects 0.000 abstract 1
239000000924 antiasthmatic agent Substances 0.000 abstract 1
239000003472 antidiabetic agent Substances 0.000 abstract 1
229940124574 antisickling agent Drugs 0.000 abstract 1
125000001769 aryl amino group Chemical group 0.000 abstract 1
125000005135 aryl sulfinyl group Chemical group 0.000 abstract 1
125000005110 aryl thio group Chemical group 0.000 abstract 1
125000004104 aryloxy group Chemical group 0.000 abstract 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
125000001589 carboacyl group Chemical group 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
230000001966 cerebroprotective effect Effects 0.000 abstract 1
210000004978 chinese hamster ovary cell Anatomy 0.000 abstract 1
238000012875 competitive assay Methods 0.000 abstract 1
239000000824 cytostatic agent Substances 0.000 abstract 1
230000001085 cytostatic effect Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 abstract 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
230000002439 hemostatic effect Effects 0.000 abstract 1
125000005241 heteroarylamino group Chemical group 0.000 abstract 1
125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
125000005150 heteroarylsulfinyl group Chemical group 0.000 abstract 1
125000005368 heteroarylthio group Chemical group 0.000 abstract 1
125000005844 heterocyclyloxy group Chemical group 0.000 abstract 1
125000004468 heterocyclylthio group Chemical group 0.000 abstract 1
208000021822 hypotensive Diseases 0.000 abstract 1
230000001077 hypotensive effect Effects 0.000 abstract 1
229960003444 immunosuppressant agent Drugs 0.000 abstract 1
230000001861 immunosuppressant effect Effects 0.000 abstract 1
239000003018 immunosuppressive agent Substances 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
230000001777 nootropic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/69—Benzenesulfonamido-pyrimidines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hematology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Glass Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Plural Heterocyclic Compounds (AREA)
Photoreceptors In Electrophotography (AREA)

NO20013586A 1999-09-03 2001-07-20 Bis-sulfonamider NO20013586L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP9906485		1999-09-03
EP0001222		2000-02-15
PCT/EP2000/007999 WO2001017976A1 (fr)	1999-09-03	2000-08-16	Bis-sulfonamides

Publications (2)

Publication Number	Publication Date
NO20013586D0 NO20013586D0 (no)	2001-07-20
NO20013586L true NO20013586L (no)	2001-07-20

Family

ID=8167417

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20013586A NO20013586L (no)	1999-09-03	2001-07-20	Bis-sulfonamider

Country Status (14)

Country	Link
US (1)	US6596719B1 (fr)
EP (1)	EP1137642B1 (fr)
CN (1)	CN100424079C (fr)
AT (1)	ATE380180T1 (fr)
AU (1)	AU775194B2 (fr)
CA (1)	CA2361402C (fr)
DE (1)	DE60037308T2 (fr)
ES (1)	ES2295048T3 (fr)
HU (1)	HUP0201402A3 (fr)
IL (1)	IL143935A (fr)
NO (1)	NO20013586L (fr)
NZ (1)	NZ512526A (fr)
WO (1)	WO2001017976A1 (fr)
ZA (1)	ZA200105130B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6720322B2 (en) *	1999-12-22	2004-04-13	Actelion Pharamceuticals Ltd.	Butyne diol derivatives
US6911476B2 (en) *	2000-03-13	2005-06-28	Eli Lilly And Company	Sulfonamide derivatives
US6387915B2 (en)	2000-05-31	2002-05-14	Pfizer Inc.	Isoxazole-sulfonamide endothelin antagonists
HU229403B1 (en) *	2000-12-18	2013-12-30	Actelion Pharmaceuticals Ltd	Novel sulfamides and their use as endothelin receptor antagonists
DE60120104T2 (de)	2001-03-20	2006-09-21	Schwarz Pharma Ag	Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
DK1243263T3 (da)	2001-03-21	2003-03-17	Sanol Arznei Schwarz Gmbh	Hidtil ukendt anvendelse af en klasse af peptidforbindelser til behandling af allodyni eller andre forskellige typer af kronisk- eller fantomsmerte
DE60224223T2 (de) *	2002-01-02	2008-12-04	Actelion Pharmaceuticals Ltd.	Neue alkylsulfonamide als endothelinantagonisten
JP4664924B2 (ja)	2003-12-02	2011-04-06	ウーツェーベーファルマゲーエムベーハー	中枢神経因性疼痛の治療のためのペプチド化合物の新規使用
CN1930135B (zh)	2004-03-05	2011-12-28	弗·哈夫曼-拉罗切有限公司	作为p2x3和p2x2/3拮抗剂的二氨基嘧啶
AU2005232395B2 (en)	2004-04-16	2010-09-09	Schwarz Pharma Ag	Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604655A1 (fr)	2004-06-09	2005-12-14	Schwarz Pharma Ag	Utilisation nouvelle de peptides pour le traitement de neuralgies trigeminales
EA014055B1 (ru)	2004-08-27	2010-08-30	Шварц Фарма Аг	Применение пептидных соединений для лечения боли при раке кости, а также боли, вызванной химиотерапией и нуклеозидами
CA2620129C (fr)	2005-09-01	2014-12-23	F. Hoffmann-La Roche Ag	Diaminopyrimidines comme modulateurs p2x3 et p2x2/3
WO2007025900A1 (fr)	2005-09-01	2007-03-08	F. Hoffmann-La Roche Ag	Diaminopyrimidines en tant que modulateurs de p2x3 et p3x2/3
CA2619919C (fr)	2005-09-01	2014-04-01	F. Hoffmann-La Roche Ag	Diaminopyrimidines en tant que modulateurs de p2x3 et p2x2/3
EA019757B1 (ru)	2006-06-15	2014-06-30	ЮСиБи ФАРМА ГМБХ	Фармацевтическая композиция с синергетическим противосудорожным эффектом
AR062501A1 (es)	2006-08-29	2008-11-12	Actelion Pharmaceuticals Ltd	Composiciones terapeuticas
MX2010001837A (es)	2007-08-17	2010-03-10	Actelion Pharmaceuticals Ltd	Derivados de 4-pirimidinasulfamida.
CN101279948B (zh) *	2008-03-14	2010-08-11	苏州博鸿化工技术有限公司	4,6-二氯-5-(2-甲氧基苯氧基)-2,2'-二嘧啶的合成方法
CN111407767B (zh) *	2020-03-28	2021-05-25	中山大学	一种磺胺间甲氧嘧啶衍生物在制备抗肿瘤药物中的应用
CN112898208B (zh) *	2021-01-29	2023-06-20	中国医科大学	苯基嘧啶胺类抗肿瘤化合物及其制备方法和应用
CN112778215B (zh) *	2021-01-29	2023-06-20	中国医科大学	2-甲氧基苯氧基嘧啶类抗肿瘤化合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL7310889A (fr) *	1972-08-12	1974-02-14
CA2162630C (fr)	1994-11-25	2007-05-01	Volker Breu	Sulfonamides
TW313568B (fr)	1994-12-20	1997-08-21	Hoffmann La Roche
US5739333A (en) *	1995-05-16	1998-04-14	Tanabe Seiyaku Co., Ltd.	Sulfonamide derivative and process for preparing the same
US5939446A (en)	1996-04-09	1999-08-17	Bristol-Myers Squibb Co.	Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists

2000
- 2000-08-16 DE DE60037308T patent/DE60037308T2/de not_active Expired - Lifetime
- 2000-08-16 CN CN00802515.0A patent/CN100424079C/zh not_active Expired - Fee Related
- 2000-08-16 AT AT00956456T patent/ATE380180T1/de not_active IP Right Cessation
- 2000-08-16 CA CA002361402A patent/CA2361402C/fr not_active Expired - Fee Related
- 2000-08-16 EP EP00956456A patent/EP1137642B1/fr not_active Expired - Lifetime
- 2000-08-16 IL IL14393500A patent/IL143935A/xx not_active IP Right Cessation
- 2000-08-16 ES ES00956456T patent/ES2295048T3/es not_active Expired - Lifetime
- 2000-08-16 WO PCT/EP2000/007999 patent/WO2001017976A1/fr not_active Ceased
- 2000-08-16 US US10/031,555 patent/US6596719B1/en not_active Expired - Fee Related
- 2000-08-16 HU HU0201402A patent/HUP0201402A3/hu unknown
- 2000-08-16 NZ NZ512526A patent/NZ512526A/xx active Application Filing
- 2000-08-16 AU AU68391/00A patent/AU775194B2/en not_active Ceased
2001
- 2001-06-21 ZA ZA200105130A patent/ZA200105130B/en unknown
- 2001-07-20 NO NO20013586A patent/NO20013586L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
ES2295048T3 (es)	2008-04-16
CA2361402A1 (fr)	2001-03-15
WO2001017976A1 (fr)	2001-03-15
IL143935A0 (en)	2002-04-21
CN100424079C (zh)	2008-10-08
NO20013586D0 (no)	2001-07-20
CA2361402C (fr)	2009-05-12
DE60037308D1 (de)	2008-01-17
ZA200105130B (en)	2002-09-23
IL143935A (en)	2005-08-31
EP1137642A1 (fr)	2001-10-04
NZ512526A (en)	2004-01-30
DE60037308T2 (de)	2008-10-30
HUP0201402A2 (en)	2002-08-28
HUP0201402A3 (en)	2003-12-29
AU6839100A (en)	2001-04-10
US6596719B1 (en)	2003-07-22
ATE380180T1 (de)	2007-12-15
AU775194B2 (en)	2004-07-22
CN1335839A (zh)	2002-02-13
EP1137642B1 (fr)	2007-12-05

Legal Events

Date	Code	Title	Description
2002-02-11	RE	Reestablishment of rights (par. 72 patents act)
2005-10-31	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
DE60037308D1 (de)	2008-01-17	Bis-sulfonamiden
AU3943189A (en)	1990-05-31	Peptides having bradykinin antagonist action
ATE219077T1 (de)	2002-06-15	Endothelin antagoniste
IS6275A (is)	2002-02-18	Heteróhringa efnasambönd og notkun þeirra sem mótlyf efnaskiptaglútamatviðtaka
DE3888568D1 (de)	1994-04-28	Menschliche peptidische Hemmungsstoffe von Leukozyten-Elastase (HLE).
DK1188768T3 (da)	2009-09-21	LHRH-antagonisk-peptider
AU6092490A (en)	1991-02-21	Peptides having bradykinin antagonist action
HUP0402282A2 (hu)	2005-02-28	Triazolo[1,5-a]kinolin-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények
IL125591A0 (en)	1999-03-12	4-aminopyrrole (3,2-d) pyrimidines as neuropeptide y receptor antagonists
EA199700147A1 (ru)	1997-12-30	Замещенные фенильные производные в качестве антагонистов эндотелина